Goldman Sachs
FHTX icon

Goldman Sachs’s Foghorn Therapeutics FHTX Stock Holding History

Goldman Sachs’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$802K Buy
164,256
+28,148
+21% +$125K ﹤0.01% 5388
2026
Q1 		$651K Buy
136,108
+17,407
+15% +$95.6K ﹤0.01% 5407
2025
Q4 		$641K Buy
118,701
+46,254
+64% +$210K ﹤0.01% 5445
2025
Q3 		$354K Buy
72,447
+37,546
+108% +$199K ﹤0.01% 5683
2025
Q2 		$164K Sell
34,901
-21,431
-38% -$89.6K ﹤0.01% 5713
2025
Q1 		$206K Sell
56,332
-18,324
-25% -$83.5K ﹤0.01% 5632
2024
Q4 		$352K Buy
74,656
+29,099
+64% +$212K ﹤0.01% 5423
2024
Q3 		$424K Buy
45,557
+30,363
+200% +$220K ﹤0.01% 5136
2024
Q2 		$87.4K Buy
15,194
+3,773
+33% +$22.5K ﹤0.01% 5414
2024
Q1 		$76.6K Sell
11,421
-2,820
-20% -$15.7K ﹤0.01% 5282
2023
Q4 		$91.9K Sell
14,241
-1,710
-11% -$7.38K ﹤0.01% 5305
2023
Q3 		$79.8K Buy
15,951
+734
+5% +$5.66K ﹤0.01% 5223
2023
Q2 		$107K Sell
15,217
-15,858
-51% -$111K ﹤0.01% 5347
2023
Q1 		$193K Sell
31,075
-2,808
-8% -$18.4K ﹤0.01% 5316
2022
Q4 		$216K Buy
33,883
+16,961
+100% +$128K ﹤0.01% 5271
2022
Q3 		$145K Buy
16,922
+544
+3% +$7K ﹤0.01% 5589
2022
Q2 		$223K Buy
16,378
+3,233
+25% +$41.7K ﹤0.01% 5593
2022
Q1 		$200K Sell
13,145
-23,298
-64% -$320K ﹤0.01% 5885
2021
Q4 		$833K Buy
36,443
+23,634
+185% +$340K ﹤0.01% 5005
2021
Q3 		$178K Buy
+12,809
New +$142K ﹤0.01% 5763
2021
Q1 		– Sell
-10,845
Closed -$220K – 6152
2020
Q4 		$220K Buy
+10,845
New +$208K ﹤0.01% 5043

Other funds holding FHTX

Flagship Pioneering
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.6B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Goldman Sachs's FHTX Position: Q2 2026 in Review

Goldman Sachs increased its Foghorn Therapeutics (FHTX) stake by 21% in Q2 2026, buying an estimated $125K and bringing the position to 164,256 shares worth $802K. The position accounts for ﹤0.01% of the portfolio, ranked #5388.

Goldman Sachs first reported a position in FHTX in Q4 2020 and has held it in 21 quarters since. The position peaked at $833K in Q4 2021. 102 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • Goldman Sachs held 164,256 shares of Foghorn Therapeutics worth $802K as of Q2 2026.
  • Goldman Sachs bought 28,148 Foghorn Therapeutics shares in Q2 2026, an estimated $125K.
  • Foghorn Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5388 holding.
  • Goldman Sachs first reported a position in Foghorn Therapeutics in Q4 2020 and has held it in 21 quarters since.
  • Goldman Sachs's Foghorn Therapeutics position peaked at $833K in Q4 2021.
  • 102 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.